Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Association of Abcb1, Μ-Opioid Receptor, and Cytochrome P450 Genes With Methadone Dose in Iranian Male Addicts Under Methadone Therapy Publisher



Golnezhad A1 ; Torkamanboutorabi A1, 2 ; Razaghi EM3 ; Zarrindast MR1, 4 ; Mahdavi MR5 ; Vousooghi N2, 4, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Research Center for Cognitive and Behavioral Sciences, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Psychiatry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Basic and Clinical Neuroscience Published:2024


Abstract

Introduction: Treatment of opioid use disorders (OUDs) via safe and effective approaches has been investigated for years. Methadone maintenance treatment (MMT) has been considered an effective therapy for opioid addiction. It has been observed that patients with genetic polymorphisms often show variability in the optimal drug dose requirement and treatment schedule. This study aimed to investigate the relationship between single nucleotide polymorphisms (SNPs) in the ATP-binding cassette subfamily B member-1 (ABCB1), the mu-opioid receptor (OPRM1), and cytochrome P450 (CYP) genes and methadone dose in patients undergoing MMT in Mazandaran Province, Iran. Methods: In a cross-sectional study, 216 male MMT patients (20 to 45 years old) who were involved in the treatment program for at least three months were randomly recruited from six MMT clinics in Mazandaran province between 2018 and 2020. Blood samples were taken, DNA was extracted, and SNPs of CYP2B6 (G516T, A785G), CYP2C19 (-3402C>T), CYP3A4 (-392A>G), OPRM (A118G), and ABCB1 (C3435T, G2677T, G2677A, and C1236T) genes were evaluated using polymerase chain reaction-restriction fragment length polymorphism (RFLP). Results: Our results showed no significant relationship between all the studied genotypes and methadone dose requirements. Conclusion: The present study, for the first time in the Mazandaran population, reported no significant correlations between methadone dose requirement and different SNPs in the ABCB1, OPRM1, and CYP genes in MMT patients, which is consistent with other studies conducted on the Iranian population. Copyright © 2024 The Author(s)
Related Docs
View other Related Docs
1. Public Health Risks Associated With Methadone in Iran: A Systematic Review and Meta-Analysis, International Journal of Drug Policy (2022)
2. Factors Influencing Engagement and Utilisation of Opium Tincture-Assisted Treatment for Opioid Use Disorder: A Qualitative Study in Tehran, Iran, Drug and Alcohol Review (2022)
3. Hiv Prevalence Among Non-Injecting People Who Use Drugs and Related Factors in Iran: A Systematic Review and Meta-Analysis, Drug and Alcohol Review (2022)
4. Buprenorphine Abuse and Health Risks in Iran: A Systematic Review, Drug and Alcohol Dependence (2021)
5. Hiv Prevention Cascades for Injection and Sexual Risk Behaviors Among Hiv-Negative People Who Inject Drug in Iran, International Journal of Drug Policy (2020)
6. Hepatitis B Virus Infection Among People Who Use Drugs in Iran: A Systematic Review, Meta-Analysis, and Trend Analysis, Harm Reduction Journal (2020)
7. Characterizing People Who Inject Drugs With No History of Opioid Agonist Therapy Uptake in Iran: Results From a National Bio-Behavioural Surveillance Survey in 2020, International Journal of Mental Health and Addiction (2022)
8. Public Injecting and Its Association With Mental Health and Other Drug-Related Outcomes Among People Who Inject Drugs in Iran, Journal of Substance Abuse Treatment (2022)
Experts (# of related papers)
View all Related Experts
Afarin Rahimi-Movaghar (19)
Alireza Noroozi (12)
Other Related Docs
9. Out-Of-Pocket Cost of Drug Abuse Consequences: Results From Iranian National Mental Health Survey; [Cout Des Paiements Directs Engendres Par L’Abus De Substances Psychoactives: Resultats De L’Enquete Nationale Iranienne Sur La Sante Mentale], Eastern Mediterranean Health Journal (2017)
10. The Evolution of Addiction Treatment and Harm Reduction Programs in Iran: A Chaotic Response or a Synergistic Diversity?, Addiction (2020)
11. Opium Dependence and the Potential Impact of Changes in Treatment Coverage Level: A Dynamic Modeling Study, Health Promotion Perspectives (2021)
12. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran, Hepatitis Monthly (2017)
13. Prevalence and Determinants of Opioid Use Disorder Among Long-Term Opiate Users in Golestan Cohort Study, BMC Psychiatry (2023)
14. Factors Influencing Transition to Shisheh (Methamphetamine) Among Young People Who Use Drugs in Tehran: A Qualitative Study, Journal of Psychoactive Drugs (2018)
15. Profile of Drug Users in the Residential Treatment Centers of Tehran, Iran, Health Promotion Perspectives (2019)
16. Prevalence, Pattern, and Associated Factors of Alcohol Use Disorder Among Male Treatment-Seeking People With Illicit Drug Use Disorder in Tehran, Iran, Journal of Substance Use (2023)
17. Opium Tincture-Assisted Treatment for Opioid Use Disorder: A Systematic Review, Journal of Substance Abuse Treatment (2021)
18. Comparison of Self-Reported Substance Use With Biological Testing Among Treatment-Seeking Patients With Opioid Use Disorder, Journal of Substance Abuse Treatment (2022)
19. Correlates of Duration Between Initial Drug Use and First Drug Injection Among People Who Inject Drugs in Iran, 2020, BMC Public Health (2025)
20. Prevalence of and Risk Factors for Hcv Among Incarcerated People at Great Tehran Prison: A Cross-Sectional Study, International Journal of Prisoner Health (2023)
21. Psychiatric Disorders Among People Living With Hiv/Aids in Iran: Prevalence, Severity, Service Utilization and Unmet Mental Health Needs, Journal of Psychosomatic Research (2018)
22. Willingness to Utilize Supervised Injection Facilities Among People Who Inject Drugs in Iran: Findings From 2020 National Hiv Bio-Behavioral Surveillance Survey, International Journal of Drug Policy (2021)
23. How Substance Use Treatment Services in Iran Survived Despite a Dual Catastrophic Situation, American Journal of Public Health (2022)
24. An Intervention to Improve Hcv Testing, Linkage to Care, and Treatment Among People Who Use Drugs in Tehran, Iran: The Enhance Study, International Journal of Drug Policy (2019)
25. Mortality and Negative Outcomes of Opioid Use and Opioid Use Disorder: A 6-Year Follow-Up Study, Addiction (2022)
26. Inpatient Buprenorphine-Assisted Withdrawal for Treatment of Vulnerable Adolescents With Opioids Use Disorder in Zahedan, Iran: An Observational Study, International Journal of High Risk Behaviors and Addiction (2019)
27. Transition to and Away From Injecting Drug Use Among Young Drug Users in Tehran, Iran: A Qualitative Study, Iranian Journal of Psychiatry and Behavioral Sciences (2017)
28. Opium Tincture Versus Methadone for Opioid Agonist Treatment: A Randomized Controlled Trial, Addiction (2023)
29. Blended Smartphone Intervention for Patients in Opioid Maintenance Treatment in Iran: Protocol for a Randomized Controlled Trial, BMC Psychiatry (2023)
30. Assessing Risk Behaviours in the Iranian General Population: Results From the Iranian Mental Health Survey; [Evaluation Des Comportements a Risque Dans La Population Generale Iranienne: Resultats De L’Enquete Iranienne Sur La Sante Mentale], Eastern Mediterranean Health Journal (2021)